Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

About this update from Pyxis Oncology, Inc.

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer. Mr. Azoulay joins Pyxis Oncology with more than 15 years of experience in corporate strategy, business development, and value-creating transactions across the biopharma industry, including deep antibody-drug conjugate (ADC) experience. In his role, he will lead corporate development strategy and pursue strategic opportunities to advance MICVO, the Company’s lead clinical asset. “We’re excited to welcome Nelson to Pyxis Oncology,” said Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology. “His deep ADC experience and strong track record in corporate strategy make him a valuable addition to the team as we work toward important milestones this year. Nelson’s appointment reflects our shared conviction in the program, and we look forward to working with him to pursue opportunities that create long-term value.” Mr. Azoulay added, “I’m thrilled to join Pyxis Oncology as we head into key clinical inflection points. The opportunity to address a significant unmet need in head and neck cancer is compelling, and I look forward to partnering with the team to build the right external relationships and help bring a meaningful treatment option to patients.” Mr. Azoulay most recently served as Senior Vice President, Strategy and Business Development, at Flagship Pioneering, where he spearheaded business development initiatives across select portfolio companies. Previously, he was Vice President of Corporate Development at ImmunoGen, where he helped shape the Company’s mid- to long-term strategy, led search and evaluation efforts, supported fundraising activities, and helped secure key transactions, including collaborations and partnerships with major pharmaceutical companies. He also played a role in ImmunoGen’s acquisition by AbbVie and subsequent integration in 2024. Earlier in his career, at PDL BioPharma, Mr. Azoulay led corporate restructuring and managed strategic divestitures. At Syneos Health Consulting, he advised global pharmaceutical and biotechnology companies on portfolio strategy, transactions, and commercial planning. He holds an MBA from Columbia Business School, an MS in Neuroscience fro...

View stock analysis, news, and events for Pyxis Oncology, Inc.